View post:
Polyrizon Receives Nasdaq Notification Regarding Minimum Bid Requirements
Related Post
- Oncotelic CEO Vuong Trieu to Present Innovative "Deciparticles" Platform at IDDST-Europe 2025 Conference in Stockholm - April 23rd, 2025
- Andrew Taylor joins Novonesis’ Executive Leadership Team - April 23rd, 2025
- Elite Clinical Network and HealthyU Clinics Announce Strategic Partnership to Expand Access to Clinical Research - April 23rd, 2025
- Digicann Ventures Provides Update Regarding Proposed RTO Transaction - April 23rd, 2025
- Sirona Biochem Announces Debenture Financing - April 23rd, 2025
- Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors - April 23rd, 2025
- Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones - April 23rd, 2025
- Pacira BioSciences to Present 104-Week Efficacy Data Following a Single Local Administration of PCRX-201 for Patients with Mild to Severe... - April 23rd, 2025
- Longeveron® Issues Letter to Shareholders Highlighting Corporate Strategy, Recent Progress and Key Priorities and Goals for 2025 - April 23rd, 2025
- UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business Updates - April 23rd, 2025
- NurExone Appoints Biotech Industry Leader - Jacob Licht to Lead U.S. Operations and Exo-Top Manufacturing Expansion and Completes Continuance into... - April 23rd, 2025
- OBI Pharma Announces Poster Presentations at the AACR 2025 Annual Meeting for OBI-992 and OBI-902 Antibody-Drug Conjugates (ADCs), GlycOBI® and... - April 23rd, 2025
- Roche receives CE Mark for its Chest Pain Triage algorithm to enhance detection of Acute Coronary Syndrome (ACS) - April 23rd, 2025
- VERAXA Biotech and Voyager Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a... - April 23rd, 2025
- Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025 - April 23rd, 2025
- Cytovation Raises US$6m to Advance Phase 2 Development of CY-101 in Adrenocortical Carcinoma to First Clinical Readouts - April 23rd, 2025
- Antag Therapeutics expands senior team to support clinical progress - April 23rd, 2025
- Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDS - April 23rd, 2025
- Boehringer Ingelheim and Tessellate Bio partner to develop first-in-class precision treatments for people with hard-to-treat cancers - April 23rd, 2025
- Orion Group Interim Report January–March 2025 - April 23rd, 2025
- Precision Neuroscience Receives FDA Clearance for High-Resolution Cortical Electrode Array - April 19th, 2025
- Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite’s Namodenoson, Leading U.S. Medical Centers Seek Authorization for... - April 19th, 2025
- Psyence Group Announces Share Consolidation - April 19th, 2025
- BVI Medical Announces Approval of Breakthrough Technology: FDA 510(k) Clearance of its Laser Endoscopy Ophthalmic System: Leos™ - April 19th, 2025
- Actum Pharma Expands Executive Team to Launch Enhanced Services Program to Support Biopharma Product Commercialization and Market Success - April 19th, 2025
- Best Testosterone Booster Supplements For Muscle Gain & Increase Testosterone For Men Over 40 Or 50 Over The Counter Pills By (Testo Prime) - April 19th, 2025
- Best Testosterone Boosters for Men Over 40 and 50: TestoPrime Under Review - April 19th, 2025
- Best Testosterone Booster Supplements Canada: TestoPrime for Males Over 40 and 50 (By TestoPrime CA) - April 19th, 2025
- Tevogen Bio Finalizes Agreement for Company’s Own Cell Therapy Production Facility - April 19th, 2025
- TELA Bio to Announce First Quarter 2025 Financial Results - April 19th, 2025
- NewAmsterdam Pharma Appoints Adele Gulfo to its Board of Directors - April 19th, 2025
- Vincerx Pharma, Inc. Announces Intent to Delist from Nasdaq and Deregister with the SEC - April 19th, 2025
- Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 19th, 2025
- Madrigal Pharmaceuticals to Release First-Quarter 2025 Financial Results and Host Webcast on May 1, 2025 - April 19th, 2025
- Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ® Among U.S. Travelers - April 19th, 2025
- Dipharma Awarded Bronze Medal by Ecovadis for Sustainability - April 19th, 2025
- Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria - April 19th, 2025
- Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU) - April 19th, 2025
- Regeneron Provides Update on EYLEA HD® (aflibercept) Injection 8 mg Supplemental Biologics License Application - April 19th, 2025
- 23andMe Provides Update Regarding Court-Supervised Sale Process - April 19th, 2025
- Longevity Health Holdings Announces Execution of Merger Agreement With 20/20 Biolabs - April 15th, 2025
- Certara Launches Non-Animal Navigator™ Solution to Help Drug Developers Reduce Reliance on Animal Testing - April 15th, 2025
- UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025 - April 15th, 2025
- Can-Fite to Generate $685M in Projected Future Revenues from its Partnerships - April 15th, 2025
- Verano Announces Promotion and Appointment of Richard Tarapchak as Chief Financial Officer - April 15th, 2025
- VIVUS Announces Enrollment of First Patient in Phase 2 Clinical Trial Assessing Ethanol-Free Carmustine as a Component of High-Dose Chemotherapy Prior... - April 15th, 2025
- [Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US - April 15th, 2025
- Prostadine Drops Reviews [We Tested It] Read Ingredients, Side Effects for Urinary System - April 15th, 2025
- Valneva Receives First Marketing Authorization for IXCHIQ® in a Chikungunya Endemic Country - April 15th, 2025
- Cara Therapeutics Announces 1-for-3 Reverse Stock Split in Connection with the Proposed Merger with Tvardi Therapeutics - April 15th, 2025
- Ipsen - March 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital - April 15th, 2025
- AB Science receives notice of allowance for Unites States patent covering masitinib until 2040 in the treatment of sickle cell disease - April 15th, 2025
- Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ’s Fifteenth Annual Bio Partnering... - April 15th, 2025
- Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 15th, 2025
- Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases - April 15th, 2025
- Cue Biopharma to Host Business Update Call and Webcast - April 15th, 2025
- BioSyent to Attend Planet MicroCap Showcase - April 15th, 2025
- Applied Therapeutics Reports Fourth Quarter and Year-end 2024 Financial Results - April 15th, 2025
- MediciNova To Participate in D. Boral’s Capital Global Conference on May 14, 2025 - April 15th, 2025
- NAYA Biosciences Announces Strategic Decision to Separate Fertility and Oncology Businesses into Distinct Operations – Company Renamed “INVO... - April 15th, 2025
- Vantage Biosciences Doses First Patient in Phase 2 Clinical Study of Oral VX-01 for Non-Proliferative Diabetic Retinopathy - April 13th, 2025
- Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025 - April 13th, 2025
- BON Announces Apple Polyphenol Commercial Order Signed - April 13th, 2025
- ImPact Biotech Announces New Data Presentations at AUA 2025 Highlighting Safety and Efficacy of Padeliporfin VTP - April 13th, 2025
- Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For VTAMA® (tapinarof) with Enhanced Therapeutic and Market Extension Prospects - April 13th, 2025
- Preliminary Results for the Year Ended 31 December 2024 - April 13th, 2025
- BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study - April 13th, 2025
- Scilex Holding Company Announces 1-for-35 Reverse Stock Split - April 13th, 2025
- Nika Pharmaceuticals, Inc. (NIKA) Latest Developments - April 13th, 2025
- Bioxytran Marks 50 years of Mitochondrial Research with BXT-25 Advancements - April 13th, 2025
- TestoPrime Reviews: Best Testosterone Booster Supplement For Men Over 40 & 50 – Is TestoPrime Tablets Safe? - April 13th, 2025
- argenx Announces Annual General Meeting of Shareholders on May 27, 2025 - April 13th, 2025
- Founder Mina Sooch Issues Open Letter to Opus Genetics Stockholders Following Withdrawal of the Restore Value Slate Amid Dilutive Financing and... - April 13th, 2025
- Organogenesis Supports CMS’ Local Coverage Determination Implementation Delay to Review Coverage Policies to Maintain Patient Access with High... - April 13th, 2025
- 4DMT Announces New Employment Inducement Grants - April 13th, 2025
- Theratechnologies Responds to Future Pak’s Press Release and Announces Exclusive Discussions with Another Potential Acquiror for the Sale of the... - April 13th, 2025
- DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document - April 13th, 2025
- Kane Biotech Announces New Agreement with Outside the Box Capital Inc. - April 13th, 2025
- Inozyme Pharma Announces JBMR Plus Publication Demonstrating Real-World Impact of ENPP1 Deficiency - April 11th, 2025
- Pluri Announces Expansion of Intellectual Property Portfolio with Two Granted Patents for 3D Expansion of Immune Cells in the United States and Israel - April 11th, 2025
Recent Comments